Key capabilities
Structural MRI
Our Structural MRI capability enables high-resolution anatomical imaging across multiple organ systems. We provide detailed visualization of soft tissues, vascular architecture, and cardiac structures, allowing precise assessment of morphology and pathology. In oncology models, we perform robust tumor volumetric analysis using optimized contrast and acquisition strategies, enabling longitudinal monitoring of tumor growth, regression, and treatment response with high reproducibility.
Brain MRI
Our Brain MRI platform integrates advanced structural and functional imaging to study neurobiology in vivo. Functional MRI (fMRI) assesses brain activation and network responses, supporting research in neurovascular coupling, disease modeling, and therapeutic evaluation. Diffusion techniques, including diffusion-weighted and diffusion tensor imaging, provide quantitative insight into tissue microstructure and white matter integrity. Together, these modalities enable comprehensive assessment of structural and functional changes in preclinical neurological models.
Hyperpolarized 13C MRS
Our Hyperpolarized ¹³C Magnetic Resonance Spectroscopy platform enables highly sensitive, real-time metabolic imaging in vivo. It visualizes and quantifies dynamic metabolic fluxes rather than static metabolite levels. Current service probes include pyruvate and ketoisocaproate, with ongoing development of new hyperpolarizable agents. This approach supports early detection of therapeutic response and provides powerful non-invasive biomarkers for translational research and drug development.
Why Work With Us
We deliver high-quality preclinical MRI grounded in rigorous experimental design and technical optimization. From study planning to data acquisition, we ensure imaging endpoints are biologically meaningful, reproducible, and aligned with translational goals.
With expertise in structural, functional, and hyperpolarized metabolic imaging, we develop customized protocols optimized for quantitative reliability. Working closely with bioinformatics and imaging experts, we support complex projects with analytical rigor.
We are not just a service provider; we are a technically rigorous imaging partner committed to strengthening translational research.
Research Team in 2023
Our Mission
Our goal is to develop imaging from a diagnostic tool into a biological discovery engine with clinical impact.
We hope to advance MRI as a quantitative research platform that enables mechanistic insights on diseases in preclinical models. By integrating structural, functional, and metabolic imaging, we seek to generate reproducible, biologically meaningful data that drive translational research.
Through technical rigor, methodological optimization, and collaboration, we aspire to bridge experimental findings with clinically relevant questions—delivering high-quality imaging that strengthens translational science.
Infrastructure
01
High-Field Preclinical MRI Systems
We operate 9.4 Tesla and 11.7 Tesla preclinical MRI systems designed for high-resolution anatomical, functional, and spectroscopic imaging. These ultra-high-field platforms enable superior signal-to-noise ratio and spatial resolution, supporting detailed structural imaging, diffusion measurements, and functional neuroimaging applications.
02
Cryogenic and Specialized RF Technology
Our neuroimaging capabilities are enhanced by a dedicated cryoprobe system for mouse brain imaging, allowing significantly improved sensitivity and spatial resolution compared to conventional surface coils. We deploy optimized RF array coils and sequence configurations for anatomical, T1- and T2-weighted imaging, FLASH and RARE acquisitions, diffusion imaging, and functional MRI studies.
03
Hyperpolarized 13C Dynamic Nuclear Polarization (DNP)
A core strength of our infrastructure is the integration of SpinAligner, a Dynamic Nuclear Polarizer (DNP) system for hyperpolarized 13C metabolic imaging. The hyperpolarization platform supports both method development and translational studies aimed at bridging preclinical findings to clinical metabolic imaging applications.
Our MRI platform builds upon Singapore’s long-standing investment in advanced bioimaging, with roots in the Singapore Bioimaging Consortium (2004–2021), which established a state-of-the-art multimodal imaging ecosystem in Biopolis. Today, our infrastructure continues this legacy by integrating high-field MRI systems with advanced metabolic imaging technologies to support translational research.